Benitec Biopharma Files S-1 Registration Statement

TL;DR

<b>Benitec Biopharma Inc. has filed an S-1 registration statement with the SEC, indicating potential future securities offerings.</b>

AI Summary

Benitec Biopharma Inc. (BNTC) filed a IPO Registration (S-1) with the SEC on May 16, 2024. Benitec Biopharma Inc. filed an S-1 registration statement with the SEC. The filing was made on May 16, 2024. The company is incorporated in Delaware and its fiscal year ends on December 31. Its principal executive offices are located at 3940 Trust Way, Hayward, California. Benitec Biopharma Inc. is classified as a non-accelerated filer and a smaller reporting company.

Why It Matters

For investors and stakeholders tracking Benitec Biopharma Inc., this filing contains several important signals. This S-1 filing signals Benitec Biopharma's intention to potentially offer securities to the public, which could involve raising capital for its operations or research and development. As a smaller reporting company and non-accelerated filer, Benitec Biopharma's filing provides updated information for investors and the market regarding its corporate structure and future plans.

Risk Assessment

Risk Level: low — Benitec Biopharma Inc. shows low risk based on this filing. The filing is a standard S-1 registration statement, which is a preliminary step for potential public offerings and does not inherently indicate immediate financial distress or significant positive developments.

Analyst Insight

Monitor future filings for details on any specific securities offerings, their terms, and the intended use of proceeds.

Key Numbers

• S-1 — Form Type (Registration Statement form)
• 2024-05-16 — Filing Date (Date the S-1 was filed)
• 333-279439 — SEC File Number (SEC registration file number)
• 2834 — SIC Code (Standard Industrial Classification Code)

Key Players & Entities

• Benitec Biopharma Inc. (company) — Registrant name
• SEC (regulator) — Filing body
• May 16, 2024 (date) — Filing date
• Delaware (jurisdiction) — State of incorporation
• 3940 Trust Way, Hayward, California (address) — Principal executive offices
• Dr. Jerel Banks (person) — Chief Executive Officer

FAQ

Industry Context

Benitec Biopharma operates in the Pharmaceutical Preparations industry (SIC code 2834).

Regulatory Implications

The filing is made under the Securities Act of 1933, which governs the registration of securities.

What Investors Should Do

1. Review the full S-1 filing for details on the proposed securities offering.
2. Track subsequent SEC filings for updates on the registration statement's effectiveness and any completed offerings.
3. Analyze the company's financial health and business strategy as disclosed in the S-1.

Key Dates

• 2024-05-16: S-1 Filing — Registration statement filed with the SEC.

Year-Over-Year Comparison

This is a new S-1 filing, so there is no prior filing to compare against for this specific registration statement.

Key Financial Figures

• $0.0001 — s) of shares of common stock, par value $0.0001 per share (the Common Stock), of Benite
• $0.0017 — nded Warrants with an exercise price of $0.0017 per share, 1,240,265 shares of Common S
• $1.93 — mmon Warrants with an exercise price of $1.93 per share, and 10,844,559 shares of Com
• $3.86 — mmon Warrants with an exercise price of $3.86 per share. We are registering the res
• $40 million — ies for gross proceeds of approximately $40 million that closed on April 22, 2024. We will
• $8.43 — Stock on The Nasdaq Capital Market was $8.43 per share. You should read this prosp
• $4.80 — e Common Stock) at a price per share of $4.80 and, in lieu of shares of Common Stock,
• $4.7999 — ck at a price per pre-funded warrant of $4.7999 (the Pre-Funded Warrants), to certain i
• $40.0 million — oss proceeds from the financing totaled $40.0 million. Net proceeds, net of commissions and o
• $37.2 million — ffering expenses, totaled approximately $37.2 million. Voting Commitment Agreement In con

Filing Documents

• d823791ds1.htm (S-1) — 289KB
• d823791dex51.htm (EX-5.1) — 10KB
• d823791dex231.htm (EX-23.1) — 2KB
• d823791dexfilingfees.htm (EX-FILING FEES) — 18KB
• g823791dsp1.jpg (GRAPHIC) — 5KB
• g823791dsp2.jpg (GRAPHIC) — 3KB
• g823791g31q10.jpg (GRAPHIC) — 26KB
• 0001193125-24-139625.txt (&nbsp;) — 367KB

Use of Proceeds

Use of Proceeds 12 Principal Stockholders 13

Description of Securities

Description of Securities 16 Selling Stockholders 19 Plan of Distribution 22 Legal Matters 24 Experts 24 Where You Can Find More Information 25 Incorporation of Documents By Reference 26 i Table of Contents ABOUT THIS PROSPECTUS Unless the context otherwise requires, the terms Benitec, the Company, we, us, our and similar terms used in this prospectus refer to Benitec Biopharma Inc., a Delaware corporation, and its subsidiaries. This prospectus is part of a registration statement on Form S-1 that we filed with the Securities and Exchange Commission (SEC). You should rely only on the information contained in or incorporated by reference into this prospectus or contained in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We have not, and the Selling Stockholders have not, authorized anyone to provide you with information that is different from that contained in such prospectuses. The Selling Stockholders are offering to sell shares of Common Stock, and are seeking offers to buy shares of Common Stock, only in jurisdictions where such offers and sales are permitted. For investors outside the United States: We have not, and the Selling Stockholders have not, taken any action that would permit this offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the offering of the securities covered hereby and the distribution of this prospectus outside the United States. The information in this prospectus is accurate only as of the date of this prospectus, regardless of the time of delivery of this prospectus or any sale of our shares of Common Stock. This prospectus and the information incorporated herein by reference contain summaries of certain provi

View Full Filing

View this S-1 filing on SEC EDGAR